Episode 321 ASCO24: CHAARTED-2 in prostate cancer - is the sequel as good as the original?

Christos Kyriakopoulos describes the outcome of this study, where cabazitaxel with abiraterone as combined with abiraterone alone in docetaxel refractory CRPC.